Ausbiotech says WA govt biased against GM

By Staff Writers
Friday, 11 February, 2005

Australian biotechnology's peak body, AusBiotech, has questioned the impartiality of Western Australia's agricultural minister Kim Chance in relation to GM crops, following the release of correspondence between the government and activitist GM groups.

According to Ausbiotech, the WA government refused to respond to correspondence from Ausbiotech regarding GM moratoria and a five-point plan for the future development and opportunities for Australian agriculture while in caretaker mode during the current election campaign.

"On the same day that AusBiotech was informed by the director general of the department of agriculture that the government cannot respond to our letter dated 24 January, a detailed letter was sent to Julie Newman, Network of Concerned Farmer, an organisation linked with Greenpeace," said executive director of Ausbiotech, Dr Tony Coulepis.

"The letter not only contained many errors of fact but also brings into question the advice that the minister is receiving in relation to agribiotech and GM crops.

"The Minister's action is not only taking away any opportunity for a level playing field, but also denying WA growers choice in canola production, as well as creating uncertainty about the pathway to market for other Australian GM innovations.

"AusBiotech is deeply concerned that the minister's attitude towards multinational companies, which jeopardises choice for growers and has a dramatic effect on small Australian companies, researchers and students in this field."

Related News

Lipid science receives new Australia-led online hub

The Lipid Network launched this month to build links between researchers, clinicians and industry...

Proposed Australian trial eyes up blood testing for Alzheimer's

Utilising networks of GPs across three states, a large-scale study intends on combining digital...

Applications open for $300K pandemic therapeutics fellowships

Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd